How a US tariff plan could reshape India’s pharma exports

The Trump administration’s latest trade initiative introduces a steep duty schedule on generic medicines imported from India, with tariffs reaching up to 200 percent after a three‑year phase‑in. The policy, effective August 1, 2026, begins with a two‑year exemption, followed by a 100 percent levy in year three and a doubling to 200 percent in year four. The stated goal is to bring generic drug manufacturing back to the United States and lessen reliance on foreign suppliers.

India’s pharmaceutical sector, which contributed $25.8 billion in total exports last fiscal year, relies heavily on the American market—accounting for nearly $10 billion or 38 percent of its pharma sales. Generic products from Indian firms treat a wide array of conditions, from chronic diseases like diabetes and hypertension to cancers and mental‑health disorders. The birth‑control segment is particularly dominated by Indian suppliers, with two companies providing roughly two‑thirds of U.S. prescriptions in 2024.

If the tariff schedule proceeds as outlined, Indian exporters that do not establish manufacturing bases in the United States could see their products become significantly more expensive for American consumers. The policy may spur investments in U.S. facilities, joint ventures, or renegotiated trade terms, but the immediate impact remains uncertain during the initial tariff‑free window.